Trade Analytics
Pharmaceuticals
Indian pharmaceutical industry supplies over 50 per cent of global demand vaccines.

Indian Pharmaceuticals Industry Analysis

Latest update: July, 2018

  • The Indian pharmaceuticals market witnessed growth at a CAGR of 5.64 per cent, during FY11-16, with the market increasing from US$ 20.95 billion in FY11 to US$ 27.57 billion in FY16. The industry’s revenues are estimated to have grown by 7.4 per cent in FY17.
  • Indian pharmaceutical market grew 5.5 per cent in CY2017 in terms of moving annual turnover. In March 2018, the market grew at 9.5 per cent year-on-year with sales of Rs 10,029 crore (US$ 1.56 billion).
  • By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and 6th largest market globally in absolute size.
  • Increase in the size of middle class households coupled with the improvement in medical infrastructure and increase in the penetration of health insurance in the country will also influence in the growth of pharmaceuticals sector.
Growth

Notes: F - Forecast, CAGR - Compound Annual Growth Rate, CY – Calendar Year, E - Estimated
Source: Department of Pharmaceuticals, PwC, McKinsey, AIOCD AWACS

  • Indian pharma companies are capitalising on export opportunities in regulated and semi-regulated markets
  • In FY17, India exported pharmaceutical products worth US$ 16.8 billion, with the number expected to reach US$ 40 billion by 2020. During April 2017–February 2018, India exported pharmaceutical products worth Rs. 767.17 billion (US$ 11.90 billion).
  • Indian drugs are exported to more than 200 countries in the world, with the US as the key market
  • India is the world’s largest provider of generic medicines; the country’s generic drugs account for 20 per cent of global generic drug exports (in terms of volumes)
  • Around 40.6 per cent of India’s US$ 16.8 billion pharmaceutical exports in 2016-17 were to the American continent, followed by a 19.7 per cent to Europe, 19.1 per cent to Africa and 18.8 per cent to Asian countries.
Growth

Notes: CAGR - Compound Annual Growth Rate, 1 – Import from April 2015-December 2015.
Source: Department of Commerce India, Department of Pharmaceuticals, India Business News, BMI

Last Updated: July, 2018

Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in UK. India contributes the second largest share of pharmaceutical and biotech workforce in the world. The pharmaceutical sector in India was valued at US$ 33 billion in 2017. In June 2018, the market grew by 12.8 per cent year-on-year with turnover of Rs 10,460 crore (US$ 1.56 billion).

With 71 per cent market share, generic drugs form the largest segment of the Indian pharmaceutical sector. Domestic API consumption is expected to reach US$ 18.8 billion by FY22. The country accounts for the second largest number of Abbreviated New Drug Applications (ANDAs) and is the world’s leader in Drug Master Files (DMFs) applications with the US Indian Drugs & Pharmaceuticals sector has received cumulative FDI worth US$ 15.72 billion between April 2000– March 2018.

Indian drugs are exported to more than 200 countries in the world, with the US as the key market. Generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years. India’s pharmaceutical exports stood at US$ 17.27 billion in 2017-18. 31 per cent of these exports from India went to the US.

The Government of India plans to set up a US$ 640 million venture capital fund to boost drug discovery and strengthen pharmaceutical infrastructure. The ‘Pharma Vision 2020’ by the government’s Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery.

Indian Pharmaceuticals Industry Report (July, 2018)

Download PDF   Download  (Size: 1.06 MB )

Indian Pharmaceuticals Industry Report (June, 2018)

Download PDF   Download  (Size: 1.07 MB )

Click to access the Pharmaceuticals Industry Archived Report

Posters

Brand India Pharma

WINNING THE WORLD

Indian pharma company have won around 40 per cent of all Abbreviated New Drug Approval (ANDA) from the US Food and Drug Administration (FDA) between j...

+ More >

Brand India Pharma

IBEF Publications

IBEF Publication

India Now Magazine


The Luxe Edge - Reshaping India's Lifestyle Choices

English

+ More Publications >

IBEF Publication

IBEF Blog - INDIA ADDA – PERSPECTIVES ON INDIA More

author_Mr_Vinay_Kalantri_Founder_MD_The_Mobil_Wallet-21.jpg "India has always had a business community not averse to risk-taking"
Vinay Kalantri, Founder and Managing Director, The Mobile Wallet

Interview with Vinay Kalantri, Founder and Managing Director, The Mobile Wallet

Founder and Managing Director of The Mobile Wallet, Vinay Kal...

author_logo-ibef1.jpg Indian fintech start-ups: At the right place, at the right time!
IBEF, Knowledge Centre

Fintech, i.e. the technology that enables banking and financial services, is a very fast growing space in India, especially for the start-up domain. Fintechs are offering...

author_logo-ibef1.jpg India: The land of technology-led start-ups!
IBEF, Knowledge Centre

The Indian technology start-up domain is proudly placed at the fourth largest position in the world. The industry was sized at US$ 35 billion in FY18. Last decade saw eme...

author_logo-ibef1.jpg India: Weaving million success stories!
IBEF, Knowledge Centre

Textiles have been one of the oldest and largest industries in India historically, second only to agriculture, and it generates jobs for millions of people. The current e...

author_Varun-Aggarwal-headshot1.jpg Leading science and technology: The opportunity and the challenges for India
Varun Aggarwal, co-founder and Head of Research, Aspiring Minds | Author of 'India Next'

Today is the most opportune time for India to revolutionise its science and technology ecosystem. The size of our economy provides the capital, manpower and market to inv...

author_Erich-Nesselhauf-MD-CEO-DICV1.JPG "We always firmly believed in the Make in India initiative. We're probably one of the most successful poster examples..."
Erich Nesselhauf, MD & CEO - Daimler India Commercial Vehicles

Daimler India Commercial Vehicle has been able to create a space for its offerings in the already crowded domestic commercial vehicle market. Erich Nesselhauf, MD & C...

ideas More

Ideas

Zuper: Dynamic Disruptor
Zuper is a B2B Software as a Service (SaaS) offering for organizations, irrespective of shape and size. It is the first in Asia to offer voice biometrics-based timesheet management of workforce. Zuper offers an end to end platform to bring together the power of people, process, product and promise. ...

JOIN IBEF.org

Join IBEF.org now. Enjoy FREE subscriptions downloads, updates and more.

Error

Already a member?
Login / Retrieve Password